Wegovy (semaglutide injection) represents the FDA-approved formulation of semaglutide indicated for chronic weight management in adults with obesity or overweight with weight-related comorbidities. Compounded semaglutide, produced by licensed pharmacies without FDA approval for weight loss, presents a clinically distinct alternative with significant manufacturing and quality control differences. While Wegovy undergoes rigorous pharmaceutical manufacturing standards with guaranteed dosage accuracy, purity specifications, and stability testing, compounded versions are prepared on a patient-by-patient basis and lack the same regulatory oversight. This distinction carries direct clinical implications: compounded semaglutide may exhibit variability in actual dose delivered, potential contaminants, altered potency over time, and inconsistent bioavailability compared to the validated Wegovy formulation. Prescribers should recognize that clinical trial data supporting semaglutide’s efficacy and safety profile in weight loss derives exclusively from FDA-approved pharmaceutical products, not compounded preparations.
The cost differential between compounded and branded products can be substantial, with compounded semaglutide typically priced significantly lower than Wegovy. However, this economic advantage must be weighed against the absence of manufacturer quality assurance, stability guarantees, and regulatory accountability. Patients using compounded semaglutide may experience unexpected variability in therapeutic response or adverse event profiles due to potency inconsistencies between batches or even within a single vial. Additionally, compounding pharmacies operate under state pharmacy board regulations rather than FDA oversight for final product approval, creating potential gaps in contamination detection and manufacturing process controls.
From a clinical standpoint, prescribers should counsel patients that while compounded semaglutide may be accessible and affordable, Wegovy remains the evidence-based, quality-assured option with predictable pharmacokinetics and documented safety profiles from clinical trials. When patients present with inadequate response or unexpected adverse effects on compounded preparations, consideration should be given to whether formulation variability rather than patient factors may be responsible. Documentation of this informed choice in the medical record is prudent given the regulatory and quality assurance distinctions between these two sources of semaglutide.
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
FAQ
What is the difference between Wegovy and compounded semaglutide?
Wegovy is an FDA-approved injectable medication manufactured by Novo Nordisk specifically for weight loss. Compounded semaglutide is made by pharmacies mixing ingredients themselves and is not FDA-approved, meaning the dosage, purity, and potency may vary from batch to batch.
Is compounded semaglutide safe to use?
Compounded semaglutide can pose safety risks because it lacks the quality control and consistency of FDA-approved medications. Variations in purity and potency between batches mean you may not receive the exact dose you think you are getting.
Why is compounded semaglutide cheaper than Wegovy?
Compounded versions skip the expensive FDA approval process and standardized manufacturing that Wegovy requires, allowing pharmacies to offer lower prices. However, the cost savings come with reduced quality assurance and regulatory oversight.
Will my insurance cover Wegovy or compounded semaglutide?
Most insurance plans do not cover Wegovy for weight loss unless you have a specific diagnosis like type 2 diabetes, though they may cover it for diabetes management. Compounded semaglutide is rarely covered by insurance since it is not FDA-approved.
How do I know if the compounded semaglutide I am taking is the right dose?
You cannot reliably verify the actual dose in compounded semaglutide without sending it to an independent laboratory for testing, which most patients do not do. This means you are relying entirely on the pharmacy’s accuracy and quality control standards.
Can my doctor prescribe Wegovy for weight loss if I do not have diabetes?
Yes, your doctor can prescribe Wegovy for chronic weight management in adults with a BMI of 30 or higher, or BMI of 27 or higher with weight-related conditions. Wegovy is specifically FDA-approved for weight loss in people without diabetes.
What happens if compounded semaglutide is contaminated or impure?
Contaminated or impure semaglutide can cause unexpected side effects, allergic reactions, or ineffective treatment. If you experience unusual symptoms, you should contact your doctor immediately and report the pharmacy to your state pharmacy board.
Is it better to buy compounded semaglutide online from other countries?
Purchasing compounded semaglutide internationally carries significant risks including counterfeit products, customs seizure, and no recourse if the medication is unsafe or ineffective. Your doctor cannot easily monitor your safety with medications from unverified overseas sources.
How should I choose between Wegovy and a compounded version if cost is a concern?
Discuss your budget and insurance coverage with your doctor, as there may be manufacturer programs or alternative options that make Wegovy more affordable. Your doctor can also help you weigh the safety and reliability differences to make the best choice for your health.
What should I do if I am currently using compounded semaglutide?
Continue your current treatment only if your doctor approves and monitor yourself closely for any unusual symptoms or changes in how the medication works. Talk with your doctor about transitioning to Wegovy or another FDA-approved option at your next appointment to ensure safety.
